United States Weighs-In on the Medtronic Case

by McDonnell Boehnen Hulbert & Berghoff LLP

MedtronicAs we previously reported, the Supreme Court granted certiorari in the Medtronic Inc. v. Boston Scientific Corp. case, where the sole issue on appeal is whether the burden of proof shifts in a declaratory judgment action brought by a licensee under Medlmmune, such that the licensee has the burden to prove that its products do not infringe the patent.  The Federal Circuit had decided this issue in the affirmative, thereby requiring Medtronic as the licensee to establish non-infringement of the licensed patents.  As we suggested, it can be presumed that the Supreme Court disagreed with this decision (because it agreed to hear the case), so the burden will likely shift back to the patentee to prove infringement in the MedImmune context.

Department of Justice (DOJ) SealThe United States filed an Amicus Curiae brief on August 2, 2013, taking just this position -- that the burden of proving infringement should never shift from the patent holder.  Most of the arguments made by the Solicitor General, however, do not adequately take into account the unique nature of this particular type of declaratory judgment jurisdiction created by the Supreme Court's MedImmune decision.  The brief does, however, highlight a few flaws in the Federal Circuit's reasoning.  In any event, it is always worthwhile to consider any brief submitted by the Solicitor General of the United States.

The first argument presented in the brief was that "the burden of proving patent infringement generally rests with the patent holder."  This is no different, however, than the Federal Circuit acknowledged in the case below.  Unfortunately, the Solicitor General's brief did not take into account the procedural uniqueness of MedImmune declaratory judgment actions.  Instead, it cited to several Supreme Court and Federal Circuit cases that predate the MedImmune case for the proposition that "the burden to prove infringement never shifts . . . ."  Imhaeuser v. Buerk, 101 U.S. 647, 662 (1880).  The brief also noted that this is the first time since the enactment of the Declaratory Jurisdiction Act that an "accused infringer" has had the burden of proving non-infringement.  But the use of the term "accused infringer" in the brief highlights the appropriateness of this argument in this context -- the declaratory-judgment plaintiff is a licensee, and therefore is not necessarily being accused of infringing.  Rather, the licensee has entered into an agreement by which it has a right to practice the patented technology.  Therefore, even though it cannot be presumed that the declaratory-judgment plaintiff has conceded infringement because of the existence of a license, the fact that Medimmune creates a unique situation must be acknowledged.

To highlight this problem, the Solicitor General takes the position that if a declaratory-judgment plaintiff must prove non-infringement, it would need "to identify and negate every conceivable theory on which the product could infringe."  This appears to be an exaggeration.  In fact, in order for a licensee to have a good-faith basis to file a Medimmune-type non-infringement action, it should have at least one reason why its product does not infringe.  And, this single reason may be enough to satisfy the burden of proof, even if the patent holder presents contrary (but not as persuasive) evidence.  The idea that the declaratory-judgment plaintiff would have to anticipate and respond to every potential theory of infringement, regardless of how unlikely, cannot be correct.

The second argument in the brief filed by the United States was that "[t]he declaratory-judgment posture does not require shifting the burden of proof otherwise associated with the parties' underlying substantive dispute."  With this argument, the Solicitor General appears to be saying that there is no reason under the rationale for declaratory-judgment jurisdiction to support a switching of burdens.  To support this proposition, the brief points out that the Supreme Court has repeatedly said that the operation of the declaratory judgment act was only procedural in nature -- it allowed the establishment of jurisdiction in cases where it might not have existed previously.  Instead, the reasoning went, if the rule established below stands, the purpose behind this act will be disserved.  This is because the act was supposed to establish a mechanism by which the patent enforcement suit could be resolved without subjecting the declaratory-judgment plaintiff to potential liability.  By changing the burden of proof, the Solicitor General pointed out, it would change the fundamental nature of that patent enforcement suit.  Correspondingly, it would change the procedural nature of the Act.

The third argument made in the Solicitor General's brief was that "[t]he existence of a license does not shift the burden of proving patent infringement from a patent holder to its licensee."  The fact that the parties entered into a license agreement does not alter the analysis for determining whether the product in question falls within the scope of the patent.  Instead, the agreement only precludes the patent holder from obtaining damages or an injunction.

The brief pointed out that the Federal Circuit was incorrect when it said that the licensee was the only party that was seeking the aid of the Court.  In other words, the licensee was not the only party seeking to "disturb the status quo."  The Solicitor General noted that Medtronic was paying money into escrow, which the patent holder would only receive if it was successful defending against the action.  Therefore, the argument goes, the patent holder also stood to benefit from the resolution of this case.  The potential flaw in that argument is that it was the license itself in that case which required the escrow payments and such payment are not inherent to such license agreements.  Therefore, to create a rule that took this into account would not necessarily be applicable in all situations.

The Solicitor General was correct, however, in that the status quo had already been disturbed.  The device in question in this case was after-arising, meaning it did not exist at the time the parties entered into the agreement.  Instead, the patent holder had to affirmatively state that this new product fell within the scope of the patents, and therefore within the scope of the agreement.  This was a disruption of the then-current status quo under the license.  It is reasonable, therefore, to view Medtronic's efforts in bringing the suit as an attempt to return the state of the parties to the status quo.

Probably one of the better arguments made by the Solicitor General centered on the chilling effect that this decision might have on a licensee that wishes to bring such an action.  The Supreme Court established MedImmune declaratory judgment actions to make it easier for licensees to challenge the licensed patents.  If the Federal Circuit's burden shifting were to stand, licensees might think twice before taking advantage of this process.  Therefore, the United States appears to be hoping that the same policy concern that prompted the Court to decide MedImmune in the first place will convince the Court to reverse the Federal Circuit's Medtronic decision.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.